EGF816

· Novartis Pharmaceuticals

Drug timelines are a Plus or Pro feature.

5 regulatory and trial events tracked for EGF816, covering 2020-10-26 to 2026-01-16. Get the full timeline:

Most recent: Clinical Trial Update: Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC [Phase 1]